
MBX Stock Forecast & Price Target
MBX Analyst Ratings
Bulls say
MBX Biosciences is a clinical-stage biotech company with a promising Precision Endocrine Peptide platform technology, optimized for extended time-action profiles and consistent drug concentration with lower dosing frequencies. With their lead compound, MBX 4291, showing a differentiated pharmacokinetic profile supporting a once-monthly dosing paradigm and potent weight loss with good GI tolerability, the potential for commercial success in the obesity market is high. The company's strong pipeline, including an amycretin prodrug candidate and a triple-agonist (GLP-1/GIP/glucagon) development candidate, further increases its potential for success. Despite risks such as clinical trial results and cash needs, the company's potential for commercial success and its pipeline developments make it a strong buy with a target price of $70 per share.
Bears say
MBX Biosciences is facing potential risks to its investment thesis, including pipeline risk as data from patients in their target indications is needed to move programs forward and no assurance that future data will continue to be positive. Additionally, commercial risk exists as there is one approved drug for their lead indication and no approved drug for post-bariatric hypoglycemia, making the eventual market opportunity uncertain. Lastly, the company will continue to incur net losses until commercialization and may need to raise additional capital, potentially impacting shareholder value.
This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
MBX Analyst Forecast & Price Prediction
Start investing in MBX
Order type
Buy in
Order amount
Est. shares
0 shares